DaxibotulinumtoxinA
- Generic Name
- DaxibotulinumtoxinA
- Brand Names
- Botox, Botox Cosmetic, Daxxify, Dysport, Xeomin
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 93384-43-1
- Unique Ingredient Identifier
- E211KPY694
- Background
DaxibotulinumtoxinA is an acetylcholine release inhibitor and neuromuscular blocking agent. It is a botulinum toxin without accessory proteins purified from the bacterium Clostridium botulinum type A, the gram-positive anaerobic bacterium primarily present in soil. C. botulinum is known to produce toxins that can cause botulism in humans.
...
- Indication
DaxibotulinumtoxinA is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients. It is also used for the treatment of cervical dystonia in adult patients.
- Associated Conditions
- Cervical Dystonia, Moderate Glabellar Frown Lines (GL), Severe Glabellar Frown Lines (GL)
- Associated Therapies
- -
A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines
- Conditions
- Interventions
- First Posted Date
- 2021-03-29
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 727
- Registration Number
- NCT04821089
- Locations
- 🇫🇷
Palais de Flore, Lyon, France
🇫🇷MEDITI - Clinique Del Mar, Antibes, France
🇫🇷Clinique de Chirurgie Esthétique Iéna, Paris, France
A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.
- Conditions
- Interventions
- First Posted Date
- 2021-02-12
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 240
- Registration Number
- NCT04752774
- Locations
- 🇺🇸
Rancho Los Amigos National Rehab, Downey, California, United States
🇺🇸Kansas Institute of Research, Overland Park, Kansas, United States
🇺🇸Quest Research Institute, Farmington Hills, Michigan, United States
Intradermal (ID) BOTOX in the Treatment of Facial Fine Lines
- First Posted Date
- 2020-11-17
- Last Posted Date
- 2021-11-16
- Lead Sponsor
- Allergan
- Target Recruit Count
- 172
- Registration Number
- NCT04631588
- Locations
- 🇺🇸
Skin and Cancer Associates, LLP /ID# 225152, Miami, Florida, United States
🇺🇸Advanced Clinical Research /ID# 225155, Salt Lake City, Utah, United States
🇺🇸Austin Institute for Clinical Research /ID# 225154, Pflugerville, Texas, United States
Study to Evaluate Subject Satisfaction With Facial Appearance and Impact of Combined Facial Treatment
- Conditions
- Interventions
- First Posted Date
- 2020-10-30
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Allergan
- Target Recruit Count
- 64
- Registration Number
- NCT04609020
- Locations
- 🇧🇷
Hospital do Servidor Publico Municipal - Sao Paulo /ID# 239165, Niteroi, Rio De Janeiro, Brazil
🇧🇷Hospital Regional da Asa Norte - Brasilia /ID# 239161, Brasilia, Brazil
🇧🇷Universidade de Sao Paulo - Sao Paulo /ID# 239163, Rio de Janeiro, Brazil
Which is More Effective in Management of Bruxism: Botox or Occlusal Splints
- Conditions
- Interventions
- First Posted Date
- 2020-04-29
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- October University for Modern Sciences and Arts
- Target Recruit Count
- 42
- Registration Number
- NCT04366869
- Locations
- 🇪🇬
MSA, Giza, Egypt
IncobotulinumtoxinA (Xeomin) to Treat Focal Hand Dystonia
- First Posted Date
- 2019-06-06
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Alain Kaelin
- Target Recruit Count
- 48
- Registration Number
- NCT03977493
- Locations
- 🇨🇭
Inselspital - University Hospital Berne, Berne, Switzerland
🇨🇭USZ- Univerity Hospital Zurich, Zurich, Switzerland
🇨🇭Neurocentro della Svizzera Italiana, Lugano, Switzerland
The Effect of Oral Baclofen and Botulinum Toxin Treatments in Hemiplegic Spasticity on the Nociceptive Flexor Reflex
- Conditions
- Interventions
- First Posted Date
- 2019-03-04
- Last Posted Date
- 2021-06-18
- Lead Sponsor
- Mustafa Kemal University
- Target Recruit Count
- 29
- Registration Number
- NCT03860662
- Locations
- 🇹🇷
Hatay Mustafa Kemal University, Hatay, Turkey
The Efficacy and Safety of CUNOX® in Patients With Moderate to Severe Glabellar Lines
- First Posted Date
- 2019-02-12
- Last Posted Date
- 2020-07-29
- Lead Sponsor
- Medy-Tox
- Target Recruit Count
- 136
- Registration Number
- NCT03837561
- Locations
- 🇷🇺
Medical Center Capital-Health, Moscow, Russian Federation
Pharmacodynamic and Safety of MT10107(Botulinum Type A Neurotoxin) in Comparison to BOTOX®
- First Posted Date
- 2019-01-08
- Last Posted Date
- 2020-08-26
- Lead Sponsor
- Medy-Tox
- Target Recruit Count
- 25
- Registration Number
- NCT03796351
- Locations
- 🇰🇷
The Catholic University of Korea, St. Paul's Hospital, Seoul, Korea, Republic of
Anhidrotic Area and Safety of MEDITOXIN in Healthy Male Valunteers
- First Posted Date
- 2018-08-27
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- Medy-Tox
- Target Recruit Count
- 13
- Registration Number
- NCT03647982
- Locations
- 🇰🇷
Catholic University St. Paul Hospital, Seoul, Dongdaemun-gu, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.